QUARTETTE (Ethinyl Estradiol; Levonorgestrel) Patent Expiration, LOE Window & CMS Spending
QUARTETTE (Ethinyl Estradiol; Levonorgestrel) by Teva Pharmaceuticals: FDA Orange Book core substance LOE 2029-03-11, 25 AB generics, $0 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Teva Pharmaceuticals |
| FDA Application & Pathway | N204061 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2029-03-11 |
| Last Listed Patent or Exclusivity Date | 2029-03-11 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 25 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 30.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.